Dexamethasone intra implant
Products billed under this code include Ozurdex.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ozurdex.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ozurdex | Allergan, Inc. | 00023-3348-07 | 7 | $1,416.968 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $202.424 | −$1.232 | 0.1 MG | Dexamethasone intra implant | v1, posted September 17, 2026 |
| 3Q26 | $203.656 | −$0.137 | 0.1 MG | Dexamethasone intra implant | v1, posted September 15, 2026 |
| 2Q26 | $203.793 | −$0.746 | 0.1 MG | Dexamethasone intra implant | v1, posted September 15, 2026 |
| 1Q26 | $204.539 | −$0.072 | 0.1 MG | Dexamethasone intra implant | v1, posted September 15, 2026 |
| 4Q25 | $204.611 | −$0.665 | 0.1 MG | Dexamethasone intra implant | v1, posted September 8, 2026 |
| 3Q25 | $205.276 | +$0.04 | 0.1 MG | Dexamethasone intra implant | v1, posted March 10, 2026 |
| 2Q25 | $205.236 | −$0.321 | 0.1 MG | Dexamethasone intra implant | v1, posted March 10, 2026 |
| 1Q25 | $205.557 | −$0.065 | 0.1 MG | Dexamethasone intra implant | v1, posted December 19, 2025 |
| 4Q24 | $205.622 | +$0.065 | 0.1 MG | Dexamethasone intra implant | v1, posted June 11, 2025 |
| 3Q24 | $205.557 | −$0.038 | 0.1 MG | Dexamethasone intra implant | v1, posted June 11, 2025 |
| 2Q24 | $205.595 | −$0.017 | 0.1 MG | Dexamethasone intra implant | v1, posted March 11, 2025 |
| 1Q24 | $205.612 | −$0.073 | 0.1 MG | Dexamethasone intra implant | v1, posted December 19, 2024 |
| 4Q23 | $205.685 | +$1.008 | 0.1 MG | Dexamethasone intra implant | v1, posted October 10, 2024 |
| 3Q23 | $204.677 | +$4.842 | 0.1 MG | Dexamethasone intra implant | v1, posted June 5, 2024 |
| 2Q23 | $199.835 | −$0.138 | 0.1 MG | Dexamethasone intra implant | v1, posted February 23, 2024 |
| 1Q23 | $199.973 | −$0.095 | 0.1 MG | Dexamethasone intra implant | v1, posted December 6, 2023 |
| 4Q22 | $200.068 | −$0.029 | 0.1 MG | Dexamethasone intra implant | v1, posted June 22, 2023 |
| 3Q22 | $200.097 | −$0.019 | 0.1 MG | Dexamethasone intra implant | v1, posted June 9, 2023 |
| 2Q22 | $200.116 | −$0.094 | 0.1 MG | Dexamethasone intra implant | v1, posted December 14, 2022 |
| 1Q22 | $200.21 | +$0.521 | 0.1 MG | Dexamethasone intra implant | v1, posted June 8, 2022 |
| 4Q21 | $199.689 | −$0.383 | 0.1 MG | Dexamethasone intra implant | v1, posted June 2, 2022 |
| 3Q21 | $200.072 | +$0.012 | 0.1 MG | Dexamethasone intra implant | v1, posted June 2, 2022 |
| 2Q21 | $200.06 | +$0.21 | 0.1 MG | Dexamethasone intra implant | v1, posted March 1, 2022 |
| 1Q21 | $199.85 | – | 0.1 MG | Dexamethasone intra implant | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.